Cortistatin exerts an immunomodulatory and neuroprotective role in a preclinical model of ischemic stroke

Ischemic stroke is the result of a permanent or transient occlusion of a brain artery, leading to irreversible tissue injury and long-term sequelae. Despite ongoing advancements in revascularization techniques, stroke remains the second leading cause of death worldwide. A comprehensive understanding...

Full description

Saved in:
Bibliographic Details
Main Authors: J. Castillo-González, L. Buscemi, P. Vargas-Rodríguez, I. Serrano-Martínez, I. Forte-Lago, M. Caro, M. Price, P. Hernández-Cortés, L. Hirt, E. González-Rey
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Pharmacological Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661824004468
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846117999928410112
author J. Castillo-González
L. Buscemi
P. Vargas-Rodríguez
I. Serrano-Martínez
I. Forte-Lago
M. Caro
M. Price
P. Hernández-Cortés
L. Hirt
E. González-Rey
author_facet J. Castillo-González
L. Buscemi
P. Vargas-Rodríguez
I. Serrano-Martínez
I. Forte-Lago
M. Caro
M. Price
P. Hernández-Cortés
L. Hirt
E. González-Rey
author_sort J. Castillo-González
collection DOAJ
description Ischemic stroke is the result of a permanent or transient occlusion of a brain artery, leading to irreversible tissue injury and long-term sequelae. Despite ongoing advancements in revascularization techniques, stroke remains the second leading cause of death worldwide. A comprehensive understanding of the complex and interconnected mechanisms, along with the endogenous mediators that modulate stroke responses is essential for the development of effective interventions. Our study investigates cortistatin, a neuropeptide extensively distributed in the immune and central nervous systems, known for its immunomodulatory properties. With neuroinflammation and peripheral immune deregulation as key pathological features of brain ischemia, cortistatin emerges as a promising therapeutic candidate. To this aim, we evaluated its potential effect in a well-established middle cerebral artery occlusion (MCAO) preclinical stroke model. Our findings indicated that the peripheral administration of cortistatin at 24 h post-stroke significantly reduced neurological damage and enhanced recovery. Importantly, cortistatin-induced neuroprotection was multitargeted, as it modulated the glial reactivity and astrocytic scar formation, facilitated blood-brain barrier recovery, and regulated local and systemic immune dysfunction. Surprisingly, administration of cortistatin at immediate and early post-stroke time points proved to be not beneficial and even detrimental. These results emphasize the importance of understanding the spatio-temporal dynamics of stroke pathology to develop innovative therapeutic strategies with appropriate time windows. Premature interruption of certain neuroinflammatory processes might inadvertently compromise neuroprotective mechanisms. In summary, our study highlights cortistatin as a novel pleiotropic therapeutic approach against ischemic stroke, offering new treatment options for patients who undergo early revascularization intervention but unsuccessful recovery.
format Article
id doaj-art-b2132a772bb74569bc46ff15b140a99e
institution Kabale University
issn 1096-1186
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series Pharmacological Research
spelling doaj-art-b2132a772bb74569bc46ff15b140a99e2024-12-18T08:47:19ZengElsevierPharmacological Research1096-11862024-12-01210107501Cortistatin exerts an immunomodulatory and neuroprotective role in a preclinical model of ischemic strokeJ. Castillo-González0L. Buscemi1P. Vargas-Rodríguez2I. Serrano-Martínez3I. Forte-Lago4M. Caro5M. Price6P. Hernández-Cortés7L. Hirt8E. González-Rey9Institute of Parasitology and Biomedicine Lopez-Neyra (IPBLN), CSIC, PT Salud, Granada 18016, SpainUniversity of Lausanne, Lausanne, Switzerland; Lausanne University Hospital, Lausanne, SwitzerlandInstitute of Parasitology and Biomedicine Lopez-Neyra (IPBLN), CSIC, PT Salud, Granada 18016, SpainInstitute of Parasitology and Biomedicine Lopez-Neyra (IPBLN), CSIC, PT Salud, Granada 18016, SpainInstitute of Parasitology and Biomedicine Lopez-Neyra (IPBLN), CSIC, PT Salud, Granada 18016, SpainInstitute of Parasitology and Biomedicine Lopez-Neyra (IPBLN), CSIC, PT Salud, Granada 18016, SpainUniversity of Lausanne, Lausanne, Switzerland; Lausanne University Hospital, Lausanne, SwitzerlandSchool of Medicine, University of Granada, Granada, SpainUniversity of Lausanne, Lausanne, Switzerland; Lausanne University Hospital, Lausanne, Switzerland; Corresponding author at: University of Lausanne, Lausanne, SwitzerlandInstitute of Parasitology and Biomedicine Lopez-Neyra (IPBLN), CSIC, PT Salud, Granada 18016, Spain; Corresponding author.Ischemic stroke is the result of a permanent or transient occlusion of a brain artery, leading to irreversible tissue injury and long-term sequelae. Despite ongoing advancements in revascularization techniques, stroke remains the second leading cause of death worldwide. A comprehensive understanding of the complex and interconnected mechanisms, along with the endogenous mediators that modulate stroke responses is essential for the development of effective interventions. Our study investigates cortistatin, a neuropeptide extensively distributed in the immune and central nervous systems, known for its immunomodulatory properties. With neuroinflammation and peripheral immune deregulation as key pathological features of brain ischemia, cortistatin emerges as a promising therapeutic candidate. To this aim, we evaluated its potential effect in a well-established middle cerebral artery occlusion (MCAO) preclinical stroke model. Our findings indicated that the peripheral administration of cortistatin at 24 h post-stroke significantly reduced neurological damage and enhanced recovery. Importantly, cortistatin-induced neuroprotection was multitargeted, as it modulated the glial reactivity and astrocytic scar formation, facilitated blood-brain barrier recovery, and regulated local and systemic immune dysfunction. Surprisingly, administration of cortistatin at immediate and early post-stroke time points proved to be not beneficial and even detrimental. These results emphasize the importance of understanding the spatio-temporal dynamics of stroke pathology to develop innovative therapeutic strategies with appropriate time windows. Premature interruption of certain neuroinflammatory processes might inadvertently compromise neuroprotective mechanisms. In summary, our study highlights cortistatin as a novel pleiotropic therapeutic approach against ischemic stroke, offering new treatment options for patients who undergo early revascularization intervention but unsuccessful recovery.http://www.sciencedirect.com/science/article/pii/S1043661824004468blood-brain barrier breakdowncortistatinischemic strokeglial responseneuroimmune regulationneuroinflammation
spellingShingle J. Castillo-González
L. Buscemi
P. Vargas-Rodríguez
I. Serrano-Martínez
I. Forte-Lago
M. Caro
M. Price
P. Hernández-Cortés
L. Hirt
E. González-Rey
Cortistatin exerts an immunomodulatory and neuroprotective role in a preclinical model of ischemic stroke
Pharmacological Research
blood-brain barrier breakdown
cortistatin
ischemic stroke
glial response
neuroimmune regulation
neuroinflammation
title Cortistatin exerts an immunomodulatory and neuroprotective role in a preclinical model of ischemic stroke
title_full Cortistatin exerts an immunomodulatory and neuroprotective role in a preclinical model of ischemic stroke
title_fullStr Cortistatin exerts an immunomodulatory and neuroprotective role in a preclinical model of ischemic stroke
title_full_unstemmed Cortistatin exerts an immunomodulatory and neuroprotective role in a preclinical model of ischemic stroke
title_short Cortistatin exerts an immunomodulatory and neuroprotective role in a preclinical model of ischemic stroke
title_sort cortistatin exerts an immunomodulatory and neuroprotective role in a preclinical model of ischemic stroke
topic blood-brain barrier breakdown
cortistatin
ischemic stroke
glial response
neuroimmune regulation
neuroinflammation
url http://www.sciencedirect.com/science/article/pii/S1043661824004468
work_keys_str_mv AT jcastillogonzalez cortistatinexertsanimmunomodulatoryandneuroprotectiveroleinapreclinicalmodelofischemicstroke
AT lbuscemi cortistatinexertsanimmunomodulatoryandneuroprotectiveroleinapreclinicalmodelofischemicstroke
AT pvargasrodriguez cortistatinexertsanimmunomodulatoryandneuroprotectiveroleinapreclinicalmodelofischemicstroke
AT iserranomartinez cortistatinexertsanimmunomodulatoryandneuroprotectiveroleinapreclinicalmodelofischemicstroke
AT ifortelago cortistatinexertsanimmunomodulatoryandneuroprotectiveroleinapreclinicalmodelofischemicstroke
AT mcaro cortistatinexertsanimmunomodulatoryandneuroprotectiveroleinapreclinicalmodelofischemicstroke
AT mprice cortistatinexertsanimmunomodulatoryandneuroprotectiveroleinapreclinicalmodelofischemicstroke
AT phernandezcortes cortistatinexertsanimmunomodulatoryandneuroprotectiveroleinapreclinicalmodelofischemicstroke
AT lhirt cortistatinexertsanimmunomodulatoryandneuroprotectiveroleinapreclinicalmodelofischemicstroke
AT egonzalezrey cortistatinexertsanimmunomodulatoryandneuroprotectiveroleinapreclinicalmodelofischemicstroke